Descripción del proyecto
Hacia un tratamiento antidepresivo personalizado en el embarazo
Hasta el 10 % de las mujeres toman medicación antidepresiva durante el embarazo. Sin embargo, la mitad de ellas interrumpe el tratamiento por miedo a los posibles efectos sobre el embrión. La interrupción del tratamiento aumenta el riesgo de recaída con profundas consecuencias. Dado que, hasta ahora, las pruebas se basan únicamente en datos epidemiológicos, a fin de determinar los factores de riesgo, el proyecto financiado con fondos europeos PregnancyAD integrará aspectos demográficos, clínicos y datos genéticos de una amplia población representativa de Dinamarca. Colmar la brecha del conocimiento en este campo ayudará a identificar a las mujeres con un elevado riesgo de recaída tras dejar los medicamentos antidepresivos durante el embarazo. Es más, contribuirá a elaborar recomendaciones óptimas sobre el tratamiento con antidepresivos durante el embarazo.
Objetivo
Antidepressants are the mainstay of pharmacological treatment for depressive and anxiety disorders in the perinatal period, and up to one in ten pregnant women take them. Among these women, over 50% discontinue antidepressants during pregnancy due to fear of possible adverse fetal effects. However, discontinuation may increase the risk of relapse, which can also have profound negative impacts. Evidence on perinatal relapse risk following antidepressant discontinuation during pregnancy is sparse and limited to highly selected populations. Moreover, the only factors considered in studies so far have been simple demographics and clinical features, while genetic profiling is conspicuously absent.
The project aims to address knowledge gaps which urgently need to be understood in order for clinical care to provide personalized antidepressant treatment recommendations around pregnancy. This overarching objective will identify women at low or high relapse risk after discontinuing antidepressants during pregnancy and determine risk factors of relapse to enable personal risk estimates for the first time, in a large representative population, combining demographics, clinical features and genetic data retrieved from Danish national registers and the Integrative Psychiatric Research (iPSYCH) cohort.
The project will provide a unique opportunity due to its multidisciplinary nature and innovative combinations of genetics and epidemiology. The proposed research will benefit from the expertise in genetics, genomics, and psychiatric epidemiology of the supervisors, and the fellow’s multidisciplinary skills in epidemiology and biostatistics applied on large, highly complicated datasets. The fellow will acquire state-of-the-art skills in the analysis of genetic data, planning, and management by training-through-research along with coursework. This project will form a fundamental leap towards her future independent career as a leading and international recognized epidemiologist.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
8000 Aarhus C
Dinamarca